Cisplatin (generic name) is a platinum-based chemotherapy drug that is widely used to treat various types of cancers. By bonding with DNA in cancer cells, it interferes with the replication of DNA to stop division and multiplication of the cells and ultimately kills them.
Although cisplatin is effective against tumors, it has number of side effects that limit its use. Major concern is nephrotoxicity (kidney damage). Patients need to be hospitalized to take hydration treatment in order to prevent renal damage. In addition, such digestive symptoms as nausea and vomiting, and poor appetite are observed.
With the aim to develop new drugs that are expected to reduce the above mentioned side effects and to increase antitumor efficacy, NanoCarrier has prepared micellar nanoparticles containing cisplatin derivatives (NC-6004) , produced by a coordination bonds of cisplatin to polyamino acid. As NC-6004 showed sustained release, as well as accumulation in cancer cells and decrease in nephrotoxicity and neurotoxicity, in May 2006, we started the phase I clinical trial in U.K.
The basic technology of this formulation was invented by Professor Kataoka of the University of Tokyo. The technology was licensed in from TOUDAI TLO Ltd. The basic Japanese patent has been granted as U.S. Pat. No. 7125546 and European Patent No. 1329221.
Although cisplatin is effective against tumors, it has number of side effects that limit its use. Major concern is nephrotoxicity (kidney damage). Patients need to be hospitalized to take hydration treatment in order to prevent renal damage. In addition, such digestive symptoms as nausea and vomiting, and poor appetite are observed.
With the aim to develop new drugs that are expected to reduce the above mentioned side effects and to increase antitumor efficacy, NanoCarrier has prepared micellar nanoparticles containing cisplatin derivatives (NC-6004) , produced by a coordination bonds of cisplatin to polyamino acid. As NC-6004 showed sustained release, as well as accumulation in cancer cells and decrease in nephrotoxicity and neurotoxicity, in May 2006, we started the phase I clinical trial in U.K.
The basic technology of this formulation was invented by Professor Kataoka of the University of Tokyo. The technology was licensed in from TOUDAI TLO Ltd. The basic Japanese patent has been granted as U.S. Pat. No. 7125546 and European Patent No. 1329221.
